Keith A Warren1, Jenni E Fox. 1. Department of Ophthalmology, University of Kansas School of Medicine, Kansas City, USA. kwarren@warrenretina.com
Abstract
PURPOSE: To evaluate the use of nepafenac 0.1% in patients with cystoid macular edema who are known steroid responders. METHODS: Patients (N = 15) with clinical and angiographic cystoid macular edema (> or = 2 months) and a history of increased intraocular pressure following administration of topical corticosteroids participated in this prospective, open-label, pilot study. All patients were treated with nepafenac 0.1% four times daily for 6 weeks and the dose was tapered off over the ensuing 6 weeks. The total treatment duration was 12 weeks. Visual acuity and retinal thickness were measured. RESULTS: For the entire population, there was a mean significant improvement in visual acuity and retinal thickness at 4 weeks and 12 weeks posttreatment compared with baseline (P < 0.0001). A subgroup analysis revealed that patients with pseudophakic cystoid macular edema (n = 11) had a mean significant improvement in visual acuity and retinal thickness compared with baseline at 4 weeks and 12 weeks posttreatment (P < 0.0001). Although the improvement in the vitreoretinal interface disorders group was not statistically different from baseline (probably due to the outlier), three of the four patients with vitreoretinal interface disorders had improvement in visual acuity and retinal thickness. Nepafenac was well tolerated. CONCLUSION: Nepafenac may be an effective and safe therapy for treating chronic cystoid macular edema in patients who are steroid responders.
PURPOSE: To evaluate the use of nepafenac 0.1% in patients with cystoid macular edema who are known steroid responders. METHODS:Patients (N = 15) with clinical and angiographic cystoid macular edema (> or = 2 months) and a history of increased intraocular pressure following administration of topical corticosteroids participated in this prospective, open-label, pilot study. All patients were treated with nepafenac 0.1% four times daily for 6 weeks and the dose was tapered off over the ensuing 6 weeks. The total treatment duration was 12 weeks. Visual acuity and retinal thickness were measured. RESULTS: For the entire population, there was a mean significant improvement in visual acuity and retinal thickness at 4 weeks and 12 weeks posttreatment compared with baseline (P < 0.0001). A subgroup analysis revealed that patients with pseudophakic cystoid macular edema (n = 11) had a mean significant improvement in visual acuity and retinal thickness compared with baseline at 4 weeks and 12 weeks posttreatment (P < 0.0001). Although the improvement in the vitreoretinal interface disorders group was not statistically different from baseline (probably due to the outlier), three of the four patients with vitreoretinal interface disorders had improvement in visual acuity and retinal thickness. Nepafenac was well tolerated. CONCLUSION:Nepafenac may be an effective and safe therapy for treating chronic cystoid macular edema in patients who are steroid responders.
Authors: Seenu M Hariprasad; Levent Akduman; Joseph A Clever; Michael Ober; Franco M Recchia; William F Mieler Journal: Clin Ophthalmol Date: 2009-06-02
Authors: Sean McCafferty; April Harris; Corin Kew; Tala Kassm; Lisa Lane; Jason Levine; Meisha Raven Journal: BMC Ophthalmol Date: 2017-02-20 Impact factor: 2.209
Authors: Alejandro Gonzalez-De la Rosa; Jose Navarro-Partida; Juan Carlos Altamirano-Vallejo; Ada Gabriela Hernandez-Gamez; Jesus Javier Garcia-Bañuelos; Juan Armendariz-Borunda; Arturo Santos Journal: J Ocul Pharmacol Ther Date: 2019-01-07 Impact factor: 2.671